<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02113683</url>
  </required_header>
  <id_info>
    <org_study_id>MMS-tm14</org_study_id>
    <nct_id>NCT02113683</nct_id>
  </id_info>
  <brief_title>Validation of MMS Test for Cancer Monitoring</brief_title>
  <acronym>MMS-TM</acronym>
  <official_title>Validation of MMS Test to Detect Active Tumor Growth of Different Cancer Types Before and After Therapy, as Well as for Subsequent Relapse Control in Comparison to Conventional Methods</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedInnovation GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>HELIOS Klinikum Berlin-Buch</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MedInnovation GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is the validation of MMS test to detect active tumor growth in
      different cancer types before and after therapy, as well as in the course of therapy and for
      subsequent relapse control compared to standard methods (clinical examination, imaging, tumor
      markers). It should be consider whether the MMS test has comparable diagnostic accuracy, and
      thus can replace more expensive or invasive procedures in future.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>active tumor growth before and after cancer therapy</measure>
    <time_frame>up to 36 month</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Colo-rectal Cancer</condition>
  <condition>Stomach Cancer</condition>
  <condition>Melanoma</condition>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>MMS test</arm_group_label>
    <description>therapy monitoring of patients with colo-rectal or stomach disease or with melanoma</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients with primary diagnosis of cancer
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of colo-rectal cancer

          -  Clinical diagnosis of stomach cancer

          -  Suspected diagnosis of melanoma

        Exclusion Criteria:

          -  Colitis ulcerosa

          -  Morbus Crohn

          -  Cancer in time period two years before

          -  Cancer therapy in time period two years before
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katja Waterstradt, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MedInnovation GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Reichardt, Dr. med.</last_name>
    <phone>+49 30 9401 548 00</phone>
    <email>peter.reichardt@helios-kliniken.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>HELIOS Klinikum Berlin-Buch, Klinik für Interdisziplinäre Onkologie</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Reichardt, Dr. med.</last_name>
      <phone>+49 30 9401 548 00</phone>
      <email>peter.reichardt@helios.kliniken.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2014</study_first_submitted>
  <study_first_submitted_qc>April 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2014</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>colo-rectal cancer</keyword>
  <keyword>stomach cancer</keyword>
  <keyword>melanoma</keyword>
  <keyword>MMS test</keyword>
  <keyword>therapy monitoring</keyword>
  <keyword>Sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

